Role of Positron Emission Mammography (PEM) Flex Solo II Positron Emission Tomography (PET) Scanner in Evaluating Neoadjuvant Chemotherapy Response in Patients With Breast Cancer

Subjects will receive bilateral (both sides) breast and axillary PEM scans. All recruited
subjects chosen for the study will have biopsy proven breast cancer and are eligible for
chemotherapy. They will undergo bilateral breast MRI for staging which is considered
standard of care. Breast MRI and PEM scans will be performed at at baseline (phase 0 or
pre-operative phase), 2nd MRI and PEM after 1 to 2 weeks of NAC (phase 1) and 3rd MRI and
PEM after 1 to 2 weeks of phase 1 (phase 2). DCE-MRI and PEM will be performed not more than
14 days apart within each phase. Cranio-Caudal (CC) and Medial Lateral Oblique (MLO) PEM
views will be performed of both the ipsilateral and contralateral breast and axillae by a
Mammography Technologist trained in mammographic positioning.

Inclusion Criteria:

- Women 18-75 years old with newly diagnosed breast cancer who are considered
candidates for breast conserving surgery (i.e., lumpectomy)

Exclusion Criteria:

- Children (< 18 years old)

- Pregnant or Lactating women

- Diabetic patients (Type I or II)

- Patients who are scheduled for a sentinel node procedure using radioactive Tc-99m
within 24 hours of PEM

- Patients who have NOT undergone a standard of care bilateral breast MRI